Afatinib versus methotrexate as second-line treatment in Asian patients with recurrent or metastatic squamous cell carcinoma of the head and neck progressing on or after platinum-based therapy (LUX-Head & Neck 3): an open-label, randomised phase III trial

BACKGROUND: Treatment options are limited for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (HNSCC) following progression after first-line platinum-based therapy, particularly in Asian countries. PATIENTS AND METHODS: In this randomised, open-label, phase III tri...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Y, Ahn, M -J, Chan, A, Wang, C -H, Kang, J -H, Kim, S -B, Bello, M, Arora, R S, Zhang, Q, He, X, Li, P, Dechaphunkul, A, Kumar, V, Kamble, K, Li, W, Kandil, A, Cohen, E E W, Geng, Y, Zografos, E, Tang, P Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927323/
https://www.ncbi.nlm.nih.gov/pubmed/31501887
http://dx.doi.org/10.1093/annonc/mdz388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6927323/
https://www.ncbi.nlm.nih.gov/pubmed/31501887
http://dx.doi.org/10.1093/annonc/mdz388

Ejemplares similares